Research ArticleCancer

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

See allHide authors and affiliations

Science Translational Medicine  07 Dec 2016:
Vol. 8, Issue 368, pp. 368ra171
DOI: 10.1126/scitranslmed.aag1298

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Immune cells join leukemia then beat it

Acute myeloid leukemia (AML) is an aggressive hematologic cancer. The only curative treatment available for this disease is hematopoietic stem cell transplantation, which can result in donor immune cells helping to eradicate the cancer. Unfortunately, this procedure is not always effective and is itself associated with numerous complications and risk of death. Rosenblatt et al. have identified a potentially better way to stimulate an immune response against AML by fusing patients’ own leukemia cells with dendritic cells. The resulting fusion cells were very effective at presenting tumor antigens to T cells, resulting in a strong antitumor T cell response and prolonged survival in human patients.

View Full Text

Stay Connected to Science Translational Medicine